SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-015814
Filing Date
2018-11-14
Accepted
2018-11-13 19:12:56
Documents
41
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 386895
2 ex31-1.htm EX-31.1 16129
3 ex31-2.htm EX-31.2 16250
4 ex32-1.htm EX-32.1 6288
5 ex32-2.htm EX-32.2 6019
  Complete submission text file 0001493152-18-015814.txt   1856072

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE nxen-20180930.xml EX-101.INS 200135
7 XBRL SCHEMA FILE nxen-20180930.xsd EX-101.SCH 30617
8 XBRL CALCULATION FILE nxen-20180930_cal.xml EX-101.CAL 23681
9 XBRL DEFINITION FILE nxen-20180930_def.xml EX-101.DEF 104408
10 XBRL LABEL FILE nxen-20180930_lab.xml EX-101.LAB 198888
11 XBRL PRESENTATION FILE nxen-20180930_pre.xml EX-101.PRE 149638
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

IRS No.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 181179917
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1